RxDoctor Payments Data

Wade Blair

Psychiatric/Mental Health · Lyons, NYNPI 1760157424

Payments from drug & device makers

$1,290in general payments, 2019–2025

Across 68 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$652
  • Johnson & Johnson$314
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Otsuka America Pharmaceutical, Inc.$61
  • Alkermes, Inc.$50
  • Indivior Inc.$26
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$1,290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,290 in reported general payments places this provider in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$7,223
Medicare patients
28
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine27$254,170
IngrezzaValbenazine Tosylate12$88,237
VraylarCariprazine Hcl39$59,314
Invega SustennaPaliperidone Palmitate17$57,483
CaplytaLumateperone Tosylate24$41,158
RexultiBrexpiprazole19$26,043
LybalviOlanzapine/Samidorphan Malate13$18,829
BelsomraSuvorexant22$10,008
TrintellixVortioxetine Hydrobromide15$7,335
Aripiprazole46$6,574
Lurasidone Hcl18$5,901
Venlafaxine Hcl ErVenlafaxine Hcl117$2,271
Bupropion XlBupropion Hcl74$1,950
Divalproex Sodium ErDivalproex Sodium34$1,608
Quetiapine Fumarate76$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$22$254,17027 claims
AbbVieVraylar$652$59,31439 claims
Johnson & JohnsonInvega Sustenna$314$57,48317 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$68$41,15824 claims
Otsuka America Pharmaceutical, Inc.Rexulti$61$26,04319 claims
Alkermes, Inc.Lybalvi$50$18,82913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Lyons

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →